In a second round of financing, French functional genomics andpharmacogenomics firm GENOME express has raised 12.4 million euros ($11.1 million). The company says it will use these additional funds to accelerate its international development in two strategic areas:
- leveraging its know-how in high-throughput DNA sequencing and related products, including DNA libraries, bioinformatics and data qualification; and - the discovery of new therapeutic targets, particularly in the fields of microbiology and the central nervous system.
The French company holds an equity position in Amplicon Express of Washington, USA, and expects to build on this and other relationships to add to its already substantial list of customers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze